NewsRx

Search our medical news database

Accelrys, Inc.

Analyst initiates coverage of nanotechnology firm with a buy rating

Published in Lab Business Week, April 17th, 2005

J. Andrew Braswell, equity analyst with Newbridge Securities Corporation, has initiated coverage on Accelrys, Inc., (ACCL), with a "Buy" rating and a 12-month price target of $9.

Accelrys is a developer and provider of molecular modeling and simulation and informatics software used for research in the life sciences and materials sciences industries, along with general nanotechnology R&D.

Molecular modeling refers to the graphical representation of materials structure at the atomic or molecular scale. These visual models are based on known mathematical data which describe the system. Simulation involves computations utilizing these data combined with...

Want to see the full article?

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Buy Now


Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Lab Business Week


NewsRx is Social

Follow us on your favorite social network by clicking on a button below:

Follow NewsRx on Twitter

NewsRx on Facebook

Awards

eHealthcare Leadership 2011 Winner
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

  • Google 2010 PageRank: #2 Among Top Health News and Media Publications
  • Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
  • Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
  • Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx on Facebook